X
Record #52438

Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial

Publisher
Wiley
Original paper date
Aug 27, 2022
Original DOI
10.1002/jmv.28097
Institution
Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran · Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran · Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran · Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran · Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran · Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran · Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran · Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran · Department of Biology, Faculty of Science, Imam Hossein University, Tehran, Iran
Open access
No
Article type
Clinical Study
Broad categories
(HSC) Medicine - Immunology(HSC) Medicine - Infectious Disease
Notes from Retraction Watch

see also https://onlinelibrary.wiley.com/doi/10.1002/jmv.28731

Citation lifecycle

How this paper is being cited

Pre-retraction
12
Same day
0
Post-retraction
3
% post-retraction
20.0%
~7.9 citations/yr before retraction · ~1.2 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse